Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2018 /
SABCS 2018: Highlights in breast cancer treatment

4th - 8th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.12.18
Views: 1705

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Dr Matteo Lambertini provides a roundup of what was being discussed in breast cancer at the SABCS 2018 congress in San Antonio with a focus on patients. 

Dr Lambertini begins by explaining the importance of the results of the KATHERINE study into patients with HER2-positive breast cancer where the use of T-DM1 antibody drug, instead of standard therapy, was shown to significantly improve outcomes for patients.

He also reports on a study on early stage breast cancer from the EBCTCG that pooled results of 11 trials adjuvant endocrine therapy after 5 years of endocrine therapy, with it being seen that extended endocrine treatment is a positive,

Dr Lambertini shares a study on triple negative breast cancer where there was found to be no benefit of extending treatment after chemotherapy to the additional agent capecitabine.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation